Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA)

Osteoporosis International

Volumn 23, Issue 2, 2012, Pages 433-443

  Landfeldt, E ^a   Strom O ^a,b,d   Robbins, S ^c   Borgstrom F ^a,b  

^a i3 Innovus   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c AMGEN INC   (United States)

^d NONE   (Sweden)

Author keywords

Compliance; Fracture risk; Persistence; Retrospective; Sweden; Treatment patterns

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; FEMALE; FRAGILITY FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; PARAMETERS; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; REGISTER; RISK REDUCTION; SWEDEN; TREATMENT WITHDRAWAL;

EID: 84857357328     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1549-6     Document Type: Article

References (35)

1. JY Reginster N Burlet 2006 Osteoporosis: a still increasing prevalence Bone 38 S4 S9 16455317 10.1016/j.bone.2005.11.024
2. EFFO NOF 1997 Who are candidates for prevention and treatment for osteoporosis Osteoporos Int 7 1 6
3. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 1493 1501 18053457 10.4065/82.12.1493
4. JA Cramer DT Gold SL Silverman EM Lewiecki 2007 A systematic review of persistence and compliance with bisphosphonates for osteoporosis Osteoporos Int 18 1023 1031 17308956 10.1007/s00198-006-0322-8 1:CAS:528:DC%2BD2sXntVOlsrY%3D
5. AN Tosteson MR Grove CS Hammond MM Moncur GT Ray GM Hebert AR Pressman B Ettinger 2003 Early discontinuation of treatment for osteoporosis Am J Med 115 209 216 12947959 10.1016/S0002-9343(03)00362-0
6. L Lamberg 2000 Patient-physician relationship critical even during brief "medication checks" Jama 284 29 31 10872001 10.1001/jama.284.1.29 1:STN:280:DC%2BD3czjt1WksA%3D%3D
7. SA Eraker JP Kirscht MH Becker 1984 Understanding and improving patient compliance Ann Intern Med 100 258 268 6362512 1:STN:280:DyaL2c7gt1OmsA%3D%3D
8. JA Cramer 1995 Relationship between medication compliance and medical outcomes Am J Health-Syst Pharm 52 S27 S29 7552915 1:STN:280: DyaK28%2Fltlyrug%3D%3D
9. AJ Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin Ther 23 1296 1310 11558866 10.1016/S0149-2918(01)80109-0 1:STN:280:DC%2BD3MrhtVKktA%3D%3D
10. AJ Carr PW Thompson C Cooper 2006 Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey Osteoporos Int 17 1638 1644 16896510 10.1007/s00198-006-0166-2 1:CAS:528:DC%2BD28XhtVagsrrI
11. SCB, Statistics Sweden. Available from: http://www.scb.se
12. The Swedish Medical Products Agency 2007 Behandling av osteoporos Information från Läkemedelsverket 18 19 38
13. B Ettinger P Chidambaran A Pressman 2001 Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs Am J Manag Care 7 597 605 11439733 1:STN:280: DC%2BD3Mzos1CmsA%3D%3D
14. The National Board of Health and Welfare. Available from: http://www.socialstyrelsen.se
15. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf PK Wong 2008 Medication compliance and persistence: terminology and definitions Value Health 11 44 47 18237359 10.1111/j.1524-4733.2007.00213.x
16. H Quan V Sundararajan P Halfon A Fong B Burnand JC Luthi LD Saunders CA Beck TE Feasby WA Ghali 2005 Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data Med Care 43 1130 1139 16224307 10.1097/01.mlr.0000182534.19832.83
17. Hosmer D, Lemeshow S (1999) Applied survival analysis: regression modeling of time to event data. Wiley, New York, p 386
18. ES Siris ST Harris CJ Rosen CE Barr JN Arvesen TA Abbott S Silverman 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 1013 1022 16901023 10.4065/81.8.1013
19. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 16197664 10.1185/030079905X61875 1:CAS:528:DC%2BD2MXhtFKqu7zP
20. E Brankin M Walker N Lynch T Aspray Y Lis W Cowell 2006 The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases Curr Med Res Opin 22 1249 1256 16834823 10.1185/030079906X112688 1:CAS:528:DC%2BD28XotlKgtLw%3D
21. JA Cramer NO Lynch AF Gaudin M Walker W Cowell 2006 The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France Clin Ther 28 1686 1694 17157124 10.1016/j.clinthera.2006.10. 013 1:CAS:528:DC%2BD28XhtlartrvP
22. H Ideguchi S Ohno K Takase A Ueda Y Ishigatsubo 2008 Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital Osteoporos Int 19 1777 1783 18458987 10.1007/s00198-008- 0618-y 1:CAS:528:DC%2BD1cXht12kur7I
23. DM Black DE Thompson DC Bauer K Ensrud T Musliner MC Hochberg MC Nevitt S Suryawanshi SR Cummings 2000 Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT Research Group J Clin Endocrinol Metab 85 4118 4124 11095442 10.1210/jc.85.11.4118 1:CAS:528:DC%2BD3cXotlWnurw%3D
24. SR Cummings DM Black DE Thompson WB Applegate E Barrett-Connor TA Musliner L Palermo R Prineas SM Rubin JC Scott T Vogt R Wallace AJ Yates AZ LaCroix 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial Jama 280 2077 2082 9875874 10.1001/jama.280.24.2077 1:CAS:528: DyaK1MXjsVWruw%3D%3D
25. J Reginster HW Minne OH Sorensen M Hooper C Roux ML Brandi B Lund D Ethgen S Pack I Roumagnac R Eastell 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Osteoporos Int 11 83 91 10663363 10.1007/s001980050010 1:CAS:528: DC%2BD3cXhvFGgsr0%3D
26. TP van Staa HG Leufkens L Abenhaim B Zhang C Cooper 2000 Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology (Oxford) 39 1383 1389 10.1093/rheumatology/39.12.1383
27. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928 16330270 10.1016/j.bone.2005.10.022
28. JJ Caro KJ Ishak KF Huybrechts G Raggio C Naujoks 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice Osteoporos Int 15 1003 1008 15167989 10.1007/s00198-004-1652-z
29. E McCloskey D de Takats J Orgee 2005 Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community based clinical trial J Bone Miner Res 20 suppl 1 S282
30. DM Black AV Schwartz KE Ensrud JA Cauley S Levis SA Quandt S Satterfield RB Wallace DC Bauer L Palermo LE Wehren A Lombardi AC Santora SR Cummings 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial Jama 296 2927 2938 17190893 10.1001/jama.296.24.2927 1:CAS:528:DC%2BD2sXnvVGh
31. GJ Strewler 2004 Decimal point-osteoporosis therapy at the 10-year mark N Engl J Med 350 1172 1174 15028820 10.1056/NEJMp048017 1:CAS:528: DC%2BD2cXit12rsLs%3D
32. HG Bone D Hosking JP Devogelaer JR Tucci RD Emkey RP Tonino JA Rodriguez-Portales RW Downs J Gupta AC Santora UA Liberman 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 1189 1199 15028823 10.1056/NEJMoa030897 1:CAS:528:DC%2BD2cXit12rsLc%3D
33. T Iizuka M Matsukawa 2008 Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients Climacteric 11 287 295 18645694 10.1080/13697130801959590 1:CAS:528:DC%2BD1cXovFWkurc%3D
34. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 15598694 10.1210/jc.2004-0952 1:CAS:528:DC%2BD2MXisVOhsr0%3D
35. S De Geest E Sabate 2003 Adherence to long-term therapies: evidence for action Eur J Cardiovasc Nurs 2 323 14667488 10.1016/S1474-5151(03)00091-4